Wedbush Issues Optimistic Estimate for PTGX Earnings

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) – Research analysts at Wedbush upped their Q2 2025 EPS estimates for shares of Protagonist Therapeutics in a note issued to investors on Wednesday, May 7th. Wedbush analyst Y. Zhong now anticipates that the company will post earnings of ($0.59) per share for the quarter, up from their prior forecast of ($0.60). Wedbush has a “Outperform” rating and a $70.00 price objective on the stock. The consensus estimate for Protagonist Therapeutics’ current full-year earnings is $2.43 per share. Wedbush also issued estimates for Protagonist Therapeutics’ Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.04) EPS, FY2026 earnings at ($2.75) EPS, FY2027 earnings at ($2.22) EPS and FY2028 earnings at ($0.43) EPS.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.31. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. The company had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million.

PTGX has been the topic of a number of other research reports. JPMorgan Chase & Co. upped their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. JMP Securities reiterated a “market outperform” rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. BTIG Research set a $73.00 price target on shares of Protagonist Therapeutics in a report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a research note on Thursday, April 10th. Finally, The Goldman Sachs Group dropped their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating on the stock in a report on Monday, February 24th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $65.44.

Protagonist Therapeutics Stock Performance

PTGX stock opened at $43.98 on Friday. Protagonist Therapeutics has a 52-week low of $26.79 and a 52-week high of $60.60. The company has a market capitalization of $2.72 billion, a P/E ratio of 16.53 and a beta of 2.65. The company has a fifty day moving average price of $46.87 and a 200-day moving average price of $42.75.

Insider Activity

In other Protagonist Therapeutics news, CFO Asif Ali sold 24,903 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total value of $1,462,553.19. Following the completion of the sale, the chief financial officer now directly owns 62,821 shares of the company’s stock, valued at approximately $3,689,477.33. This represents a 28.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Arturo Md Molina sold 30,514 shares of Protagonist Therapeutics stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the transaction, the insider now directly owns 83,892 shares in the company, valued at approximately $4,676,140.08. This represents a 26.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,532 shares of company stock worth $3,665,786 over the last 90 days. 5.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Protagonist Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of PTGX. Bank of Montreal Can lifted its holdings in Protagonist Therapeutics by 4.5% during the fourth quarter. Bank of Montreal Can now owns 6,250 shares of the company’s stock valued at $241,000 after purchasing an additional 270 shares during the last quarter. GF Fund Management CO. LTD. lifted its holdings in Protagonist Therapeutics by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,526 shares of the company’s stock worth $74,000 after purchasing an additional 275 shares in the last quarter. Maryland State Retirement & Pension System increased its position in shares of Protagonist Therapeutics by 1.4% during the fourth quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock valued at $779,000 after buying an additional 278 shares during the period. Nisa Investment Advisors LLC grew its stake in Protagonist Therapeutics by 10.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after acquiring an additional 295 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its holdings in Protagonist Therapeutics by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock worth $1,112,000 after acquiring an additional 300 shares during the period. 98.63% of the stock is owned by institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.